



**University of Illinois Cancer Center
SUMMER CME SERIES
PROGRAM OVERVIEW**

DATES/TOPICS:

JUNE 11, 2025 – BREAST CANCER
JUNE 18, 2025 – GENERAL ONCOLOGY
JUNE 25, 2025 – HEMATOLOGIC MALIGNANCIES

LOCATION:

mHUB
1623 W Fulton Street
Chicago, IL 60612
312-248-8701
www.mhubchicago.com

TARGET AUDIENCE:

The series' target audience includes medical oncologists, hematologists, pathologists, oncology nurses, fellows, residents, advanced practice providers, family practitioners, primary care practitioners, allied health professionals, and other providers interested in the care of patients with cancer.

SESSION 1:

JUNE 11, 2025 – BREAST CANCER

SESSION CHAIR:



Abiola Ibraheem, MD

Title: Assistant Professor
Division of Hematology/Oncology
Department of Medicine
Center for Global Health
University of Illinois Cancer Center
Chicago, IL

EDUCATIONAL GOAL:

The goal of this CME activity is to enhance participants' knowledge and competence in the latest advancements in targeted therapies for cancer treatment. By integrating emerging evidence, optimizing therapeutic strategies, and addressing adverse event management, clinicians will be better equipped to improve patient outcomes and personalize cancer care.

LEARNING OBJECTIVES:

After participating in these activities, learners will be better able to:

1. **Evaluate** the evolving landscape of **HER2-targeted therapies** and their role in optimizing treatment strategies for various cancer types.
2. **Analyze** the clinical efficacy and safety profiles of **next-generation hormone therapies and PI3K inhibitors** beyond CDK4/6 inhibitors in cancer treatment.
3. **Assess** the potential benefits and challenges of **combining immunotherapies with antibody-drug conjugates (ADCs)** to enhance therapeutic outcomes.
4. **Understand** evidence-based strategies for **managing adverse effects of targeted therapies**, improving patient adherence, and optimizing overall treatment efficacy.

PRELIMINARY SESSION AGENDA:

1:00 PM	2:00 PM	Registration, Exhibits and Lunch
2:00 PM	2:05 PM	Introduction
2:05 PM	2:50 PM	HER2-Targeted Therapies
2:50 PM	3:35 PM	Beyond CDK4/6 Inhibitors: Exploring Next-Generation Hormone Therapies and PI3K Inhibitors in Cancer Treatment
3:35 PM	4:35 PM	Break, Exhibits, Non-CME Ancillary Event, and Afternoon Pick-Me-Up
4:35 PM	5:20 PM	Combining Target Mechanisms: Immunotherapies and Antibody-Drug Conjugates
5:20 PM	6:05 PM	Managing Adverse Effects of Targeted Therapies: Strategies for Optimizing Patient Outcomes
6:05 PM	7:00 PM	Networking Event

SESSION 2:

JUNE 18, 2025 – GENERAL ONCOLOGICAL CANCERS

SESSION CHAIR:



VK Gadi, MD, PhD

Deputy Director, University of Illinois Cancer Center

Professor and Director, Medical Oncology,

UIC Department of Medicine

University of Illinois Cancer Center

Chicago, IL

EDUCATIONAL GOAL:

The goal of this CME activity is to provide oncology professionals with the latest evidence-based updates on the diagnosis, treatment, and emerging therapies for lung and pancreatic cancers, as well as the evolving role of antibody-drug conjugates (ADCs) and management strategies for CNS metastases. This program aims to enhance clinical decision-making and optimize patient outcomes through a multidisciplinary approach.

LEARNING OBJECTIVES:

After participating in these activities, learners will be better able to:

1. **Incorporate** the latest advancements in the management of **early-stage and late-stage lung cancer**, including emerging therapeutic approaches.
2. **Analyze** new developments in **pancreatic cancer treatment**, with a focus on novel therapies and evolving clinical guidelines.
3. **Assess** the expanding role of **antibody-drug conjugates (ADCs)** in oncology and determine their appropriate integration into treatment strategies.
4. **Evaluate** current approaches to **CNS metastases management**, assessing progress and identifying areas for continued improvement in patient care.

PRELIMINARY SESSION AGENDA:

1:00 PM	2:00 PM	Registration, Exhibits and Lunch
2:00 PM	2:05 PM	Introduction
2:05 PM	2:50 PM	Lung Cancer: Updates on Early-Stage and Late-Stage Disease
2:50 PM	3:35 PM	Pancreatic Cancer: A Refresher and the Latest Advances
3:35 PM	4:35 PM	Break, Exhibits, Non-CME Ancillary Event, and Afternoon Pick-Me-Up
4:35 PM	5:20 PM	Do We Really Need All These ADCs?
5:20 PM	6:05 PM	CNS Metastases: Are We Making Progress?
6:05 PM	7:00 PM	Networking Event

SESSION 3:

JUNE 25, 2025 – HEMATOLOGIC MALIGNANCIES

SESSION CHAIR:



Carlos Galvez, MD
University of Illinois Cancer Center
Chicago, IL

EDUCATIONAL GOAL:



This CME activity aims to enhance clinicians’ understanding of cutting-edge treatment strategies in hematologic malignancies, including advancements in CAR T-cell therapy, novel triple-drug regimens for relapsed/refractory AML, and the evolving role of BCMA-targeted therapies and minimal residual disease (MRD) testing in multiple myeloma. By integrating the latest clinical data, participants will be better equipped to optimize patient outcomes through individualized and evidence-based treatment approaches.

LEARNING OBJECTIVES:

After participating in these activities, learners will be better able to:

1. **Evaluate** current and emerging **CAR T-cell therapy strategies** for lymphoid malignancies, including patient selection and response optimization.
2. **Analyze** the clinical efficacy and safety of **triple-drug regimens** in the treatment of relapsed/refractory acute myeloid leukemia (AML).
3. **Assess** the latest developments in **BCMA-targeted treatment strategies** for multiple myeloma and their impact on therapeutic decision-making.
4. **Integrate minimal residual disease (MRD) testing** into multiple myeloma treatment decisions to optimize long-term patient outcomes.

PRELIMINARY SESSION AGENDA:

1:00 PM	2:00 PM	Registration, Exhibits and Lunch
2:00 PM	2:05 PM	Introduction
2:05 PM	2:50 PM	CAR T-Cell Therapy Strategies in Lymphoid Malignancies
2:50 PM	3:35 PM	Emerging Triple-Drug Regimens for Relapsed/Refractory AML
3:35 PM	4:35 PM	Break, Exhibits, Non-CME Ancillary Event, and Afternoon Pick-Me-Up
4:35 PM	5:20 PM	Advances in BCMA-Targeted Treatment Strategies for Multiple Myeloma
5:20 PM	6:05 PM	The Role of MRD Testing in Treatment Decisions and Outcomes for Multiple Myeloma
6:05 PM	7:00 PM	Networking Event